NCT Number: NCT00355446
Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.
The purpose of this study is to assay human aqueous for bimatoprost and the presence of any metabolites, especially prostaglandin analogs. Hypothesis:Bimatoprost is not metabolized to a prostaglandin F-2-alpha analog in human eyes
* Bimatoprost levels in human aqueous peak approximately three hours post dosing
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
IU Eye at Carmel, Indianapolis, Indiana, United States
About this study
The purpose of this study is to assay human aqueous for bimatoprost and the presence of any metabolites, especially prostaglandin analogs
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- All subjects must:
- Be willing and able to provide written Informed Consent.
- Be able and willing to follow instructions and likely to complete the entire course of the study.
- Be male or female of any race at least 18 years of age.
- Have visually significant cataract for which they have elected to undergo cataract surgery..
Exclusion criteria
- No subject may:
- Have any contraindication to use of a prostaglandin analog or prostamide derivative.
- Have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study parameters (such as: uveitis, ocular infection, or severe dry eye). Patients with mild chronic blepharitis, age-related macular degeneration, background diabetic retinopathy may be enrolled at the discretion of the investigator.
- Have laser or any other intraocular surgery within the past three months. 5. Require use of ocular medications (including glaucoma medications), except intermittent use of artificial tears. Patients may not have a history of ever having used a prostaglandin analog topically.
- Have known allergy or sensitivity to the study medications or their components 7. Have corneal abnormalities that would interfere with the ability to obtain an adequate sample safely or have a shallow anterior which would make obtaining an aqueous sample difficult at the time of surgery in the opinion of the investigator.
- Be concurrently enrolled in an investigational drug or device study or participation within the last 30 days in any investigational drug or device study.
- Be pregnant, nursing, planning a pregnancy, or be of childbearing potential and not using a reliable form of contraception (a woman is considered of childbearing potential unless she is postmenopausal, has had a uterus and/or both ovaries removed, or has had a bilateral tubal ligation).
- Have a situation or condition that in the investigator's opinion may put the subject at significant risk, may confound the study results, or may interfere significantly with participation in the study.
Treatment and study plan
Primary outcomes
-
Bimatoprost free acid in human aqueous
Sponsors and collaborators
Lead sponsor
Indiana University
Other
Registry information
Official study title
Bioavailabilty of Bimatoprost Ophthalmic Solution in Human Aqueous.
Important dates
- Study start
- 2001
- Study completion
- 2004
- First posted
- Jul 24, 2006
- Registry last updated
- Oct 17, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Effect of Trypan Blue on Corneal Endothelial Cell Count During Phacoemulsification
NCT07735000
Age Related Cataract, Cataract
Peshawar, KPK, Pakistan
View Trial DetailsEffect of Intravenous Mannitol on Anterior Chamber Depth and Intraocular Pressure.
NCT07605260
Cataract, Eye Diseases
Islamabad, Punjab Province, Pakistan
View Trial DetailsEvaluation of a Monofocal Intraocular Lens
NCT06428955
Cataract, Eye Diseases
Indianapolis, Indiana, United States
View Trial DetailsVisual Performance of Patients Implanted With a Multifocal IOL
NCT06111222
Cataract, Eye Diseases
Heidelberg, Germany
View Trial Details